nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily)	gefitinib alone	progression-free survival (PFS) and B. overall survival (OS)	10498	10674	With a median follow-up duration of 22.1 months, the PFS rate at 3 months was 37.2% in nimotuzumab plus gefitinib and 48.1% in gefitinib [HR 0.99; 95% CI, 0.70-1.38; P = 0.95].
nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily)	gefitinib alone	progression-free survival (PFS) and B. overall survival (OS)	10675	10893	The median PFS and OS were 2.0 months and 14.5 months in nimotuzumab plus gefitinib and 2.8 months and 13.2 months in gefitinib [HR 0.99; 95% CI, 0.70-1.38; P = 0.95 for PFS; HR 0.93, 95% CI 0.63-1.38, P = 0.72 for OS]
nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily)	gefitinib alone	progression-free survival (PFS) and B. overall survival (OS)	-1	-1	Nimotuzumab plus gefitinib was not found to have superior PFS compared with gefitinib monotherapy C. in patients with EGFR mutations (10.3 vs. 7.4 months in gefitinib alone, P = 0.42) or D. wild type EGFR patients (1.0 vs. 2.3 months in gefitinib alone, P = 0.85).
gefitinib alone	baseline	progression-free survival (PFS)	10675	10905	The median PFS and OS were 2.0 months and 14.5 months in nimotuzumab plus gefitinib and 2.8 months and 13.2 months in gefitinib [HR 0.99; 95% CI, 0.70-1.38; P = 0.95 for PFS; HR 0.93, 95% CI 0.63-1.38, P = 0.72 for OS] (Figure 2).
